APIMEDS PHARMACEUTICALS US I (APUS)
Institutional ownership reported to the SEC as of Q2 2026, across 5 quarters.
7
Reporting holders
$383.7K
Reported value
2.8%
Of shares outstanding
0.0%
Held as options
+1
Holder change
Institutions report 426,282 shares against 15,091,177 outstanding. Shares only - option lines are excluded, which is why this can be compared with the company at all. The count comes from the cover page of the company's own most recent report, so it is dated when that was filed rather than at quarter end.
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Hemenway Trust Co LLC | $246.6K | 274,000 | 0.02% | 4q | HELD |
| VANGUARD CAPITAL MANAGEMENT LLC | $57.3K | 63,654 | 0.00% | 2q | -33.6%-$29.0K |
| GEODE CAPITAL MANAGEMENT, LLC | $31.6K | 35,114 | 0.00% | 4q | -12.3%-$4.4K |
| VANGUARD FIDUCIARY TRUST CO | $21.6K | 24,039 | 0.00% | 2q | HELD |
| JANE STREET GROUP, LLC | $14.4K | 15,993 | 0.00% | new | NEW |
| UBS Group AG | $10.6K | 11,818 | 0.00% | 3q | +182.3%+$6.9K |
| Tower Research Capital LLC (TRC) | $1.5K | 1,664 | 0.00% | new | NEW |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 7 | $383.7K | 426,282 | 2 | 1 | 2 | 0.0% |
| Q1 2026 | 6 | $803.0K | 448,756 | 1 | 2 | 0 | 0.0% |
| Q4 2025 | 7 | $648.9K | 395,700 | 3 | 3 | 0 | 0.0% |
| Q3 2025 | 7 | $687.8K | 386,419 | 5 | 1 | 0 | 0.0% |
| Q2 2025 | 6 | $490.2K | 278,531 | 5 | 0 | 0 | 0.0% |